ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION

(19)

(11)

EP 4 241 784 A3

(12)	EUROPEAN PATENT APPLICATION

(88)	Date of publication A3:
	15.11.2023 Bulletin 2023/46

(43)	Date of publication A2:
	13.09.2023 Bulletin 2023/37

(21)	Application number: 23168817.7

(22)	Date of filing: 11.12.2015

(51)

International Patent Classification (IPC):

C12N 15/67^(2006.01)
A61K 31/7105^(2006.01)
A61K 39/00^(2006.01)

C12N 15/85^(2006.01)
A61K 31/711^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C12N 15/67; A61K 2039/53; A61K 2039/54; C12N 2760/16134; Y02A 50/30

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

12.12.2014 WO PCT/EP2014/003334

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	21209125.0 / 4023755
	20157801.0 / 3708668
	15817068.8 / 3230458

(71)	Applicant: CureVac SE
	72076 Tübingen (DE)

(72)	Inventors:
	Theß, Andreas 72076 Tübingen (DE) Schlake, Thomas 72076 Tübingen (DE) Grund, Stefanie 72076 Tübingen (DE)

(74)	Representative: Graf von Stosch Patentanwaltsgesellschaft mbH
	Prinzregentenstraße 22 80538 München 80538 München (DE)

(54)	ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION

(57) The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3'-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

Search report

Search report